Welcome to our dedicated page for CRISPR Therapeutics SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a mix of equity awards, an option exercise, and a mandated share sale. On March 20, 2026, he received a stock option covering 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026. He was also granted 27,500 restricted stock units (RSUs), scheduled to vest in four annual tranches from March 20, 2027 through March 20, 2030.
On the same date, 6,250 RSUs from a prior 2024 award vested and were converted into 6,250 Common Shares. On March 23, 2026, Raju sold 3,708 Common Shares at an average price of $46.78 per share. A footnote states this sale was required to cover tax withholding on the RSU vesting under the company’s RSU Settlement Policy and "does not represent a discretionary trade". After these transactions, he directly held 15,565 Common Shares, which remain subject to a lock-up agreement related to the issuer’s convertible senior notes due 2031.
CRISPR Therapeutics AG granted equity awards to its Chief Medical Officer, Naimish Patel. On March 20, 2026, he received stock options covering 38,499 common shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026.
He was also awarded 30,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on March 20 of 2027, 2028, 2029 and 2030. Both awards are recorded as direct ownership and reflect compensation-related acquisitions rather than open-market purchases.
CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported routine equity compensation activity, including RSU vesting and a mandated tax-related sale. On March 14, 2026, 8,125 Restricted Stock Units converted into 8,125 Common Shares at $0.00 per share, representing the first quarter of a 32,500-share RSU grant awarded on March 14, 2025.
A separate footnote explains that 3,150 Common Shares were sold at $48.26 per share on March 16, 2026 solely to cover tax withholding obligations tied to this vesting, as required by the company’s RSU Settlement Policy, and that this did not represent a discretionary trade. Following these transactions, Patel directly owns 13,143 Common Shares, including 592 acquired under the 2016 Employee Stock Purchase Plan, and holds 24,375 unvested Restricted Stock Units that continue to vest annually through March 14, 2029.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised and vested restricted stock units and related common shares, then disposed of a portion mainly for tax obligations and a gift. On March 14, 2026, he acquired 16,875 common shares through the conversion of restricted stock units granted in 2023 and 2025. On March 16, 2026, 9,869 common shares were sold at $48.26 per share to satisfy tax withholding requirements under the company’s RSU Settlement Policy, and 750 shares were transferred as a bona fide gift without consideration. After these transactions, he directly held 13,023 common shares, which remain subject to a lock-up related to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported RSU vesting and a related share sale. On March 14, 2026, 6,875 restricted stock units converted into 6,875 common shares at $0.00 per share, as part of a 27,500-share RSU grant vesting annually from 2026 to 2029.
On March 16, 2026, he sold 3,450 common shares at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, he directly holds 91,240 common shares and 20,625 restricted stock units, with remaining shares subject to a lock-up agreement tied to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related tax sale. On March 14, 2026, 20,625 Restricted Stock Units vested and were converted into 20,625 Common Shares at a conversion price of $0.00 per share.
The vested RSUs are part of an 82,500-share award granted on March 14, 2025, scheduled to vest in four equal annual installments through March 14, 2029. On March 16, 2026, 10,349 Common Shares were sold at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnotes state does not represent a discretionary trade. After these transactions, Kulkarni directly holds 245,834 Common Shares and 61,875 Restricted Stock Units.
CRISPR Therapeutics completed a private offering of $600.0 million aggregate principal amount of convertible senior notes due 2031, generating approximately $585.2 million in net proceeds for general corporate purposes. The notes are senior unsecured obligations with an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax.
Holders may convert at an initial rate of 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a 45.0% premium to the $52.80 last reported sale price on the Nasdaq Global Market on March 10, 2026. Initially, a maximum of 11,363,580 common shares may be delivered upon conversion based on the initial maximum conversion rate.
The notes mature on March 1, 2031, pay interest semiannually starting September 1, 2026, and are redeemable at the company’s option on or after March 6, 2029 if share price conditions are met. They were sold in an unregistered Rule 144A private placement, and the shares issuable upon conversion are expected to be delivered in transactions exempt under Section 3(a)(9).
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported an RSU vesting and related share sale. On March 10, 2026, he acquired 5,500 Common Shares at $0.00 per share through the exercise of Restricted Stock Units, reflecting part of a 22,000-share award granted on March 10, 2023.
On March 11, 2026, he sold 2,800 Common Shares at an average price of $52.80 per share. A footnote states these shares were sold to cover tax withholding obligations under the company’s RSU Settlement Policy and were not a discretionary trade. After these transactions, he directly owned 87,815 Common Shares.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported compensation-related share activity. On March 10, 2026, 19,250 restricted stock units were exercised into 19,250 Common Shares at $0.00 per share, reflecting vesting of part of a prior equity award.
On March 11, 2026, 9,798 Common Shares were sold at $52.80 per share. A footnote explains this amount was required to be sold to cover tax withholding tied to the RSU vesting under the company’s RSU Settlement Policy, and therefore did not represent a discretionary trade. After these transactions, Kulkarni directly held 235,558 Common Shares.
CRISPR Therapeutics AG is raising capital through a private offering of $550 million aggregate principal amount of convertible senior notes due 2031, sold to qualified institutional buyers. The offering was upsized from a previously proposed $350 million.
The notes carry an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax, and mature on March 1, 2031 unless earlier converted, redeemed or repurchased. They are initially convertible at 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a roughly 45% premium to the $52.80 share price on March 10, 2026. CRISPR Therapeutics estimates net proceeds of approximately $536.3 million, or $585.2 million if the purchasers’ option is fully exercised, and plans to use the funds for general corporate purposes.